Clinical Trial Update: A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation [Phase 3]

View source ↗

Summary

Phase 3 trial results for lumacaftor in combination with ivacaftor in cystic fibrosis patients aged 12 and older with F508del homozygous CFTR mutation; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Lumacaftor/Ivacaftor

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation | Phase 3 | Status: COMPLETED | Results posted: 2015-09-01